boswellic acid: ursane type; RN given refers to (3alpha,4beta)-isomer; active principle of salai guggal; see also record for salai guggal [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 168928 |
| CHEMBL ID | 267225 |
| CHEBI ID | 192014 |
| SCHEMBL ID | 4385785 |
| MeSH ID | M0154146 |
| PubMed CID | 637234 |
| CHEMBL ID | 395428 |
| SCHEMBL ID | 4379676 |
| MeSH ID | M0154146 |
| Synonym |
|---|
| beta-boswellic acid |
| smr000445587 |
| MLS000697685 |
| boswellic acid |
| urs-12-en-23-oic acid, 3-hydroxy-, (3alpha,4beta)- |
| bdbm50241260 |
| CHEMBL267225 , |
| (3r,4r,4ar,6ar,6bs,8ar,11r,12s,12ar,14ar,14br)-3-hydroxy-4,6a,6b,8a,11,12,14b-heptamethyl-2,3,4a,5,6,7,8,9,10,11,12,12a,14,14a-tetradecahydro-1h-picene-4-carboxylic acid |
| CHEBI:192014 |
| NCGC00247633-01 |
| unii-b252m1yo2v |
| b252m1yo2v , |
| AKOS015897120 |
| (4r)-3alpha-hydroxyurs-12-en-24-oic acid |
| LMPR0106180011 |
| urs-12-en-24-oic acid, 3.alpha.-hydroxy- |
| urs-12-en-23-oic acid, 3-hydroxy-, (3.alpha.,4.beta.)- |
| .beta.-boswellic acid (constituent of boswellia serrata) [dsc] |
| .beta.-boswellic acid |
| 3.alpha.-hydroxyurs-12-en-24-oic acid |
| .beta.-boswellic acid [mi] |
| SCHEMBL4385785 |
| DTXSID2057578 |
| AC-30252 |
| beta-boswellic acid, analytical standard |
| (3alpha,4beta)-3-hydroxy-urs-12-en-23-oic acid |
| (3alpha,4beta)-3-hydroxy-urs-12-en-23-oate |
| HY-N2513 |
| 3-hydroxy-12-ursen-24-oic acid |
| CS-0022784 |
| Q27274271 |
| 471-66-9 |
| alpha-boswellic acid |
| CHEMBL395428 , |
| S5391 |
| (4r)-3alpha-hydroxyolean-12-en-24-oic acid |
| LMPR0106150027 |
| CS-3735 |
| SCHEMBL4379676 |
| HY-N0611 |
| bdbm50237598 |
| alpha-boswellic acid, analytical standard |
| a-boswellic acid |
| boswellic acid, alpha |
| AKOS032962053 |
| -boswellic acid |
| 3alpha-hydroxy-12-oleanen-24-oic acid |
| Q63392254 |
| CCG-269302 |
| AC-34683 |
Boswellic acid (BA) is a secondary metabolite from the pentacyclic terpenoid compound groups that are derived from the plant genus Boswellia. It is an important plant-derived natural product with tremendous pharmacological potential. It has been reported to inhibit the growth of several types of cancer cells.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Boswellic acids have been recognized as anti-inflammatory and immunomodulatory agents with potentials to control autoimmune and inflammatory diseases. " | ( Effect of Boswellic acids on T cell proliferation and activation. Al-Harrasi, A; Elkord, E; Meyiah, A; Shawkat, MY; Ur Rehman, N, 2023) | 2.76 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Boswellic acids inhibit the transformation of arachidonic acid to leukotrienes via 5-lipoxygenase but can also enhance the liberation of arachidonic acid in human leukocytes and platelets. " | ( Boswellic acids stimulate arachidonic acid release and 12-lipoxygenase activity in human platelets independent of Ca2+ and differentially interact with platelet-type 12-lipoxygenase. Jauch, J; Kather, N; Poeckel, D; Tausch, L; Werz, O, 2006) | 3.22 |
Rats treated with boswellic acids (125 or 250 mg/kg) or pioglitazone showed improved insulin sensitivity and a reduction in liver index, activities of liver enzymes, serum TNF-α and IL-6.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pre-treatment with boswellic acids decreased level of all the measured parameters and decreased the severity of myocardial damage as supported by histopathological studies." | ( Cardioprotective effect of boswellic acids against doxorubicin induced myocardial infarction in rats. Anjum, I; Mushtaq, MN; Riaz, S; Shahid, MH, 2021) | 1.24 |
| "Rats treated with boswellic acids (125 or 250 mg/kg) or pioglitazone showed improved insulin sensitivity and a reduction in liver index, activities of liver enzymes, serum TNF-α and IL-6 as well as hepatic iNOS expression and HNE formation compared to HFD group." | ( Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. Abdelaziz, EZ; Barakat, BM; Bilasy, SE; Farag, NE; Fawzy, MS; Zaitone, SA, 2015) | 1.06 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, the pharmacokinetic profile of its anti-inflammatory bioactive compounds has not been elucidated." | ( Comparative pharmacokinetic study of two boswellic acids in normal and arthritic rat plasma after oral administration of Boswellia serrata extract or Huo Luo Xiao Ling Dan by LC-MS. Ai, Y; Dai, R; Lee, DY; Wang, H; Wu, Y; Zhang, C, 2014) | 0.67 |
| "01) all the pharmacokinetic parameters, such as Cmax, AUC0-n, AUCtotal, t1/2, and mean residence time, and decreased the clearance, Vd, markedly as compared with the control group." | ( Pharmacokinetic and Pharmacodynamic Interaction of Boswellic Acids and Andrographolide with Glyburide in Diabetic Rats: Including Its PK/PD Modeling. Samala, S; Veeresham, C, 2016) | 0.69 |
Twelve-week use of curcumin complex reduces pain-related symptoms in patients with OA. Curcuvet in combination with Boswellic acid could be considered a valid aid in a multimodal treatment for canine osteoarthritis.
| Excerpt | Reference | Relevance |
|---|---|---|
| " The objective of the present study is to enhance bioavailability of boswellic acid by its complexation with phosphatidylcholine." | ( Complexation with phosphatidyl choline as a strategy for absorption enhancement of boswellic acid. Dixit, VK; Gupta, NK; Sharma, A, 2010) | 0.82 |
| " In addition, the preliminary pharmacokinetic studies of these compounds using various standard methods show their poor bioavailability in humans and rodents, which has led to questions of their pharmacological relevance and potentially limits their use in clinical practice and pharmaceutical development." | ( Prospects of boswellic acids as potential pharmaceutics. Du, Z; Liu, Y; Liu, Z; Lu, A; Ning, Z; Song, Z; Wang, C, 2015) | 0.79 |
| " The results revealed that BA and AD led to the PK/PD changes because of glyburide-increased bioavailability and because of the inhibition of CYP3A4 enzyme." | ( Pharmacokinetic and Pharmacodynamic Interaction of Boswellic Acids and Andrographolide with Glyburide in Diabetic Rats: Including Its PK/PD Modeling. Samala, S; Veeresham, C, 2016) | 0.69 |
| " Pharmacokinetic investigations of BAs uncover its poor bioavailability through digestive system thus creates a need for improved therapeutic responses which can possibly be achieved by developing formulations through novel delivery system." | ( Development and optimization of boswellic acid-loaded proniosomal gel. Dureja, H; Garg, M; Mehta, M, 2016) | 0.72 |
| " Phytoproflex® is characterized by an innovative delivery system that improves bioavailability of curcuminoids and could be useful in the management of OA." | ( Phytoproflex®: supplementary management of osteoarthrosis: a supplement registry. Belcaro, G; Corti, A; Dugall, M; Eggenhoffner, R; Feragalli, B; Ganguly, A; Giacomelli, L; Hosoi, M; Hu, S; Ledda, A; Luzzi, R, 2018) | 0.48 |
| "Native extracts of curcumin and boswellia are known to exert antiinflammatory properties but have poor bioavailability when given orally." | ( Micellar solubilisation enhances the antiinflammatory activities of curcumin and boswellic acids in rats with adjuvant-induced arthritis. Abdel-Tawab, M; Behnam, D; El-Hazek, RM; El-Sabbagh, WA; Frank, J; Khayyal, MT, 2018) | 0.71 |
| " Even though it is shown to have anti-inflammatory activity, its bioavailability gets limited due to its poor aqueous solubility and permeability." | ( Ex-vivo intestinal absorption study of boswellic acid, cyclodextrin complexes and poloxamer solid dispersions using everted gut sac technique. Mokashi, P; Pandita, N; Tambe, A, 2019) | 0.78 |
| " Previous research suggested that the bioavailability of a drug can be influenced by physical properties." | ( The Effects of Vinegar Processing on the Changes in the Physical Properties of Frankincense Related to the Absorption of the Main Boswellic Acids. Liang, D; Liu, Y; Liu, Z; Lu, A; Ning, Z; Peng, S; Song, Z; Wan, X; Wang, C, 2019) | 0.72 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " After daily intraperitoneal dosage the extract of mixed acetylboswellic acids (20 mg/kg) significantly reduced the clinical symptoms in guinea pigs with experimental autoimmune encephalomyelitis (EAE) between days 11 and 21." | ( Effects of boswellic acids extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoimmune encephalomyelitis. Ammon, HP; Metzger, G; Neu, IS; Safayhi, H; Vogel, U; Wehrmann, M; Wildfeuer, A, 1998) | 0.93 |
| " To prevent an uncritical use of H 15, further studies with prospective central documentation have to be initiated to evaluate the clinical indications for H 15 in palliative therapy, optimal dosage and duration of application." | ( Boswellic acids in the palliative therapy of children with progressive or relapsed brain tumors. Bode, U; Breu, H; Dohrn, B; Engelbrecht, V; Göbel, U; Janssen, G, ) | 1.57 |
| " However, which of these pharmacological actions contribute to the therapeutic effects and which is finally the best dosage of a standardized extract needs further examination." | ( Modulation of the immune system by Boswellia serrata extracts and boswellic acids. Ammon, HP, 2010) | 0.6 |
| "According to a randomized cross-over design with two treatments, two sequences and two periods, 12 volunteers alternatively received the lecithin-formulated Boswellia extract (CSP) or the non-formulated Boswellia extract (BE) at a dosage of 2×250mg capsules." | ( A single-dose, randomized, cross-over, two-way, open-label study for comparing the absorption of boswellic acids and its lecithin formulation. Abdel-Tawab, M; Allegrini, P; Appendino, G; Artaria, C; Meins, J; Morazzoni, P; Riva, A; Savio, D; Schubert-Zsilavecz, M, 2016) | 0.65 |
| Class | Description |
|---|---|
| triterpenoid | Any terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 39.8107 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 89.1251 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Prostaglandin E synthase | Homo sapiens (human) | IC50 (µMol) | 5.0000 | 0.0010 | 2.0308 | 10.0000 | AID1153839; AID1357408; AID691832 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | IC50 (µMol) | 40.0000 | 0.0003 | 2.1774 | 10.0000 | AID1617778 |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | IC50 (µMol) | 40.0000 | 0.0001 | 1.6847 | 9.3200 | AID1617774 |
| Tyrosine-protein phosphatase non-receptor type 2 | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.7000 | 4.5804 | 9.4500 | AID409687 |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | IC50 (µMol) | 20.0000 | 0.0005 | 3.4984 | 9.7600 | AID409686 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 (µMol) | 40.0000 | 0.0001 | 0.9950 | 10.0000 | AID1617780 |
| Prolyl endopeptidase | Homo sapiens (human) | IC50 (µMol) | 9.7500 | 0.0011 | 1.9896 | 9.7500 | AID378147 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | IC50 (µMol) | 40.0000 | 0.0003 | 2.1774 | 10.0000 | AID1617778 |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | IC50 (µMol) | 42.0000 | 0.0001 | 1.6847 | 9.3200 | AID1617774 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0400 | 2.0998 | 10.0000 | AID1443725 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 (µMol) | 40.0000 | 0.0001 | 0.9950 | 10.0000 | AID1617780 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 0.9970 | 0.0600 | 8.9128 | 130.5170 | AID1902 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1272076 | Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression at 10 uM after 5 hrs | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6. |
| AID638482 | Induction of apoptosis in p53-deficient human HL60 cells assessed as post-apoptotic cells at 50 uM after 6 hrs by FITC-conjugated annexinV/PI-based flow cytometric analysis (Rvb = 1 %) | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. |
| AID1272080 | Anti-inflammatory activity in BALB/c mouse assessed as inhibition of LPS-induced IL-6 expression at 10 mg/kg, po pre-treated for 1 hr followed by LPS administration measured 2.5 hrs after LPS challenge by ELISA | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6. |
| AID1617781 | Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as residual activity at 42 uM using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis r | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID307619 | Antiinflammatory activity against carrageenan-induced paw edema in Wistar rat assessed as reduction of paw edema at 250 mg/kg after 4 hrs relative to control | 2007 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13 | Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats. |
| AID1272078 | Cytotoxicity against human FR2 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6. |
| AID307618 | Antiinflammatory activity against carrageenan-induced paw edema in Wistar rat assessed as reduction of paw edema at 250 mg/kg after 3 hrs relative to control | 2007 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13 | Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats. |
| AID303272 | Cytotoxicity against human 502713 cells at 10 uM after 48 hrs | 2007 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23 | Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids. |
| AID1204861 | Inhibition of IL-1 beta-induced LOX activity in human SW982 cells assessed as enzyme activity at LD50 treated for 24 hrs prior to incubation with IL-1 beta for 6 hrs (Rvb = 100.0%) | 2015 | European journal of medicinal chemistry, Jun-15, Volume: 98 | Synthesis and biological evaluation of boswellic acid-NSAID hybrid molecules as anti-inflammatory and anti-arthritic agents. |
| AID691832 | Inhibition of mPGES1 | 2012 | Journal of natural products, Oct-26, Volume: 75, Issue:10 | Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present. |
| AID691830 | Plasma concentration in rat at 240 mg/kg, po administered using compound, Lipoid S100 and pluronic f127 ratio 1:1:1 formulation relative to non-formulated compound after 4 to 6 hrs | 2012 | Journal of natural products, Oct-26, Volume: 75, Issue:10 | Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present. |
| AID307622 | Antiarthritic activity against Mycobacterium tuberculosis-induced rat arthritic model assessed as inhibition of chronic phase inflammation at 250 mg/kg relative to control | 2007 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13 | Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats. |
| AID303269 | Cytotoxicity against human MCF7 cells at 10 uM after 48 hrs | 2007 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23 | Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids. |
| AID638422 | Induction of necrosis in p53-deficient human HL60 cells at 50 uM after 6 hrs by FITC-conjugated annexinV/PI-based flow cytometric analysis | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. |
| AID638413 | Anticancer activity against human SW620 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. |
| AID638414 | Anticancer activity against human COLO205 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. |
| AID691833 | Ratio drug level in brain to plasma of rat at 240 mg/kg, po after 8 hrs | 2012 | Journal of natural products, Oct-26, Volume: 75, Issue:10 | Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present. |
| AID1357408 | Inhibition of mPGES1 in human A549 cell microsomal membrane using pGH2 as substrate pretreated for 15 mins followed by substrate addition and measured after 1 min by RP-HPLC method | 2018 | European journal of medicinal chemistry, Jun-10, Volume: 153 | Plant-derived mPGES-1 inhibitors or suppressors: A new emerging trend in the search for small molecules to combat inflammation. |
| AID638415 | Anticancer activity against human Hep2 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. |
| AID1272077 | Anti-inflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-6 expression at 10 uM after 5 hrs | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6. |
| AID691785 | Drug level in rat brain at 240 mg/kg, po administered using compound, Lipoid S100 and pluronic f127 ratio 1:1:1 formulation | 2012 | Journal of natural products, Oct-26, Volume: 75, Issue:10 | Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present. |
| AID1868239 | Inhibition of recombinant human SENP1 assessed as reduction in deSUMOylation of RanGAP1-SUMO1 at 5 uM using RanGAP1-SUMO1 as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins relative to control | 2022 | Journal of natural products, 05-27, Volume: 85, Issue:5 | Discovery of Natural Ursane-type SENP1 Inhibitors and the Platinum Resistance Reversal Activity Against Human Ovarian Cancer Cells: A Structure-Activity Relationship Study. |
| AID303273 | Cytotoxicity against human HT29 cells at 10 uM after 48 hrs | 2007 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23 | Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids. |
| AID409686 | Inhibition of PTP1B by pNPP assay | 2008 | Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18 | Oleanolic acid and its derivatives: new inhibitor of protein tyrosine phosphatase 1B with cellular activities. |
| AID1617777 | Inhibition of human recombinant N-terminal His-tagged 15-LOX2 expressed in Escherichia coli assessed as residual activity at 42 uM using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID638483 | Induction of apoptosis in p53-deficient human HL60 cells assessed as apoptotic cells at 50 uM after 6 hrs by FITC-conjugated annexinV/PI-based flow cytometric analysis (Rvb = 5 %) | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. |
| AID638412 | Anticancer activity against human HT-29 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. |
| AID409687 | Inhibition of TCPTP by pNPP assay | 2008 | Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18 | Oleanolic acid and its derivatives: new inhibitor of protein tyrosine phosphatase 1B with cellular activities. |
| AID378147 | Inhibition of prolyl endopeptidase | 2005 | Journal of natural products, Feb, Volume: 68, Issue:2 | Bioactive constituents from Boswellia papyrifera. |
| AID590119 | Cytotoxicity against human HL60 cells after 48 hrs by MTT assay | 2011 | European journal of medicinal chemistry, Apr, Volume: 46, Issue:4 | A comparative study of proapoptotic potential of cyano analogues of boswellic acid and 11-keto-boswellic acid. |
| AID691783 | Ratio drug level in brain to plasma of rat at 240 mg/kg, po administered using compound, Lipoid S100 and pluronic f127 ratio 1:1:1 formulation after 8 hrs | 2012 | Journal of natural products, Oct-26, Volume: 75, Issue:10 | Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present. |
| AID638417 | Anticancer activity against human PC3 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. |
| AID303271 | Cytotoxicity against human SW620 cells at 10 uM after 48 hrs | 2007 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23 | Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids. |
| AID638423 | Induction of autophagy in p53-deficient human HL60 cells at 50 uM after 6 hrs by acridine orange staining | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. |
| AID1617778 | Inhibition of ovine recombinant COX1 assessed as decrease in formation of PGE2 using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID590124 | Cytotoxicity against human HeLa cells after 48 hrs by MTT assay | 2011 | European journal of medicinal chemistry, Apr, Volume: 46, Issue:4 | A comparative study of proapoptotic potential of cyano analogues of boswellic acid and 11-keto-boswellic acid. |
| AID638416 | Anticancer activity against human DU145 cells assessed as growth inhibition at 50 uM after 48 hrs by SRB assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. |
| AID691784 | Drug level in rat brain at 240 mg/kg, po | 2012 | Journal of natural products, Oct-26, Volume: 75, Issue:10 | Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present. |
| AID303270 | Cytotoxicity against human DU145 cells at 10 uM after 48 hrs | 2007 | Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23 | Cytotoxic and apoptotic activities of novel amino analogues of boswellic acids. |
| AID1204860 | Inhibition of IL-1 beta-induced COX-2 activity in human SW982 cells assessed as enzyme activity at LD50 treated for 24 hrs prior to incubation with IL-1 beta for 6 hrs (Rvb = 100.0%) | 2015 | European journal of medicinal chemistry, Jun-15, Volume: 98 | Synthesis and biological evaluation of boswellic acid-NSAID hybrid molecules as anti-inflammatory and anti-arthritic agents. |
| AID1617775 | Inhibition of human recombinant 5-LOX expressed in insect cells assessed residual activity using arachidonic acid at 42 uM as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric ion oxidation-xylenol o | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID1153839 | Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis | 2014 | Journal of natural products, Jun-27, Volume: 77, Issue:6 | Tetra- and pentacyclic triterpene acids from the ancient anti-inflammatory remedy frankincense as inhibitors of microsomal prostaglandin E(2) synthase-1. |
| AID1272079 | Anti-inflammatory activity in BALB/c mouse assessed as inhibition of LPS-induced TNFalpha expression at 10 mg/kg, po pre-treated for 1 hr followed by LPS administration measured 2.5 hrs after LPS challenge by ELISA | 2016 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2 | Analogues of boswellic acids as inhibitors of pro-inflammatory cytokines TNF-α and IL-6. |
| AID1617779 | Inhibition of ovine recombinant COX1 assessed as residual activity at 42 uM using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID1617774 | Inhibition of human recombinant 5-LOX expressed in insect cells assessed as decrease in production of 5-HPETE and 5-HETE using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric io | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID1204859 | Cytotoxicity against human SW982 cells after 24 hrs by MTT assay | 2015 | European journal of medicinal chemistry, Jun-15, Volume: 98 | Synthesis and biological evaluation of boswellic acid-NSAID hybrid molecules as anti-inflammatory and anti-arthritic agents. |
| AID1617780 | Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID1617776 | Inhibition of human recombinant N-terminal His-tagged 15-LOX2 expressed in Escherichia coli using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric ion oxidation-xylenol orange as | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID638419 | Anticancer activity against human HL60 cells after 48 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | Acyl derivatives of boswellic acids as inhibitors of NF-κB and STATs. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1443725 | Inhibition of 15-LOX (unknown origin) | 2017 | Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8 | Easy and rapid preparation of benzoylhydrazides and their diazene derivatives as inhibitors of 15-lipoxygenase. |
| AID1617780 | Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID1617775 | Inhibition of human recombinant 5-LOX expressed in insect cells assessed residual activity using arachidonic acid at 42 uM as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric ion oxidation-xylenol o | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID307619 | Antiinflammatory activity against carrageenan-induced paw edema in Wistar rat assessed as reduction of paw edema at 250 mg/kg after 4 hrs relative to control | 2007 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13 | Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats. |
| AID1617781 | Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as residual activity at 42 uM using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis r | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID691833 | Ratio drug level in brain to plasma of rat at 240 mg/kg, po after 8 hrs | 2012 | Journal of natural products, Oct-26, Volume: 75, Issue:10 | Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present. |
| AID1617776 | Inhibition of human recombinant N-terminal His-tagged 15-LOX2 expressed in Escherichia coli using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric ion oxidation-xylenol orange as | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID307622 | Antiarthritic activity against Mycobacterium tuberculosis-induced rat arthritic model assessed as inhibition of chronic phase inflammation at 250 mg/kg relative to control | 2007 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13 | Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats. |
| AID307618 | Antiinflammatory activity against carrageenan-induced paw edema in Wistar rat assessed as reduction of paw edema at 250 mg/kg after 3 hrs relative to control | 2007 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13 | Boswellic acids and glucosamine show synergistic effect in preclinical anti-inflammatory study in rats. |
| AID691783 | Ratio drug level in brain to plasma of rat at 240 mg/kg, po administered using compound, Lipoid S100 and pluronic f127 ratio 1:1:1 formulation after 8 hrs | 2012 | Journal of natural products, Oct-26, Volume: 75, Issue:10 | Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present. |
| AID1617778 | Inhibition of ovine recombinant COX1 assessed as decrease in formation of PGE2 using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID1617779 | Inhibition of ovine recombinant COX1 assessed as residual activity at 42 uM using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID1617777 | Inhibition of human recombinant N-terminal His-tagged 15-LOX2 expressed in Escherichia coli assessed as residual activity at 42 uM using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID691830 | Plasma concentration in rat at 240 mg/kg, po administered using compound, Lipoid S100 and pluronic f127 ratio 1:1:1 formulation relative to non-formulated compound after 4 to 6 hrs | 2012 | Journal of natural products, Oct-26, Volume: 75, Issue:10 | Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present. |
| AID1617774 | Inhibition of human recombinant 5-LOX expressed in insect cells assessed as decrease in production of 5-HPETE and 5-HETE using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric io | 2019 | Journal of natural products, 12-27, Volume: 82, Issue:12 | Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes. |
| AID691784 | Drug level in rat brain at 240 mg/kg, po | 2012 | Journal of natural products, Oct-26, Volume: 75, Issue:10 | Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present. |
| AID691785 | Drug level in rat brain at 240 mg/kg, po administered using compound, Lipoid S100 and pluronic f127 ratio 1:1:1 formulation | 2012 | Journal of natural products, Oct-26, Volume: 75, Issue:10 | Effect of phospholipid-based formulations of Boswellia serrata extract on the solubility, permeability, and absorption of the individual boswellic acid constituents present. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (0.91) | 18.7374 |
| 1990's | 9 (4.11) | 18.2507 |
| 2000's | 52 (23.74) | 29.6817 |
| 2010's | 111 (50.68) | 24.3611 |
| 2020's | 45 (20.55) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (34.30) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 15 (6.61%) | 5.53% |
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 28 (12.33%) | 6.00% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (0.44%) | 4.05% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 183 (80.62%) | 84.16% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Renal Stones With Frankincense (Boswellic Acid): A Clinical Randomized Trial [NCT03924596] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2019-09-30 | Not yet recruiting | ||
| Evaluation of the Efficacy of Natural JAK_ STAT Pathways Inhibitors in Treatment of Patients With Rheumatoid Arthritis as a Complementary Medicine [NCT05788705] | 75 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | |||
| Safety, Tolerability And Mechanism Of Action Of Boswellic Acids In Multiple Sclerosis and Clinically Isolated Syndrome: A MRI-Controlled, Multicenter, Baseline-To-Treatment, 32-Weeks, Open-Label, Phase IIa Trial [NCT01450124] | Phase 2 | 29 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||